Azienda Unita Sanitaria Locale Toscana Nord Ovest
- Address
- Via Enrico Mattei 21, 54100 Massa, Italy
Cardiovascular Diseases
At Azienda Unita Sanitaria Locale Toscana Nord Ovest in Massa, cardiovascular research focuses on stroke and acute ischemic stroke, including patients at high risk after a transient ischemic event. The trials are designed to test new treatment approaches and better understand how to lower the chance of further brain injury.
- Preventing recurrent ischemic stroke after a recent event
- Evaluating treatment options for high-risk transient ischemic attack
- Assessing whether therapies can improve outcomes after intracerebral hemorrhage
This work aims to improve clinical decision-making in urgent cerebrovascular disease and support more effective care for patients at risk of serious complications.
Neoplasms
Research in neoplasms at this site centers on cervical cancer and precancerous cervical disease, with studies exploring ways to reduce recurrence after treatment. The main goal is to improve prevention and follow-up care for women treated for high-grade cervical lesions.
- Studying HPV vaccination as a way to reduce post-surgical disease recurrence
- Focusing on cervical intraepithelial neoplasia and early invasive cervical cancer
- Supporting better long-term outcomes after conization and related procedures
This area reflects a broader effort to strengthen cancer prevention and refine strategies for patients with early-stage gynecologic disease.
Respiratory Tract Diseases
Within respiratory tract diseases, the site is studying chronic obstructive pulmonary disease in people with a history of exacerbations. The research is aimed at testing whether adding a new therapy to standard care can help reduce flare-ups and improve day-to-day disease control.
- Reducing moderate to severe COPD exacerbations
- Evaluating add-on treatment strategies for persistent respiratory symptoms
- Exploring better ways to manage disease burden in former smokers
These studies support efforts to improve quality of life and treatment effectiveness in chronic lung disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1University Of Nottingham1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Unita Sanitaria Locale Toscana Nord Ovest
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Acetylsalicylic Acid | 1 | Unknown | 2023-08-04 | 2023-08-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.